Vapendavir
Based on 4 publication(s) in Google Scholar
Vapendavir (BTA798) is a potent enteroviral capsid binder (CB). Vapendavir (BTA798) possesses potent antiviral activity for enterovirus 71 (EV71) replication, with EC50 values of 0.5-1.4 μM in different EV71 strains.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 439085-51-5
- Formule: C21H26N4O3
- Masse moléculaire:382.46
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Vapendavir
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | EC50 |
0.001 μg/mL
Compound: 6, BTA798
|
Antirhinoviral activity against Human rhinovirus 2 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antirhinoviral activity against Human rhinovirus 2 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 24900468] |
| HeLa | EC50 |
0.005 μg/mL
Compound: 6, BTA798
|
Antirhinoviral activity against Human rhinovirus 14 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antirhinoviral activity against Human rhinovirus 14 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 24900468] |
| HeLa | EC50 |
1.9 ng/mL
Compound: 6, BTA798
|
Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antirhinoviral activity against minor receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 24900468] |
| HeLa | EC50 |
2.7 ng/mL
Compound: 6, BTA798
|
Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antirhinoviral activity against antiviral-resistant Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 24900468] |
| HeLa | EC50 |
3.8 ng/mL
Compound: 6, BTA798
|
Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antirhinoviral activity against Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 24900468] |
| HeLa | EC50 |
5 ng/mL
Compound: 6, BTA798
|
Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antirhinoviral activity against Human rhinovirus B infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 24900468] |
| HeLa | EC50 |
5.2 ng/mL
Compound: 6, BTA798
|
Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antirhinoviral activity against major receptor-resistant Human rhinovirus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 24900468] |
| HeLa | EC50 |
5.7 ng/mL
Compound: 6, BTA798
|
Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
Antirhinoviral activity against antiviral-resistant Human rhinovirus A infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 24900468] |
| MRC5 | CC50 |
>20 μM
Compound: Vapendavir
|
Cytotoxicity against human MRC5 cells
Cytotoxicity against human MRC5 cells
|
[PMID: 39088999] |
| RD | CC50 |
>63 μM
Compound: Vapendavir
|
Cytotoxicity against human RD cells
Cytotoxicity against human RD cells
|
[PMID: 39088999] |
Vapendavir (BTA798) efficiently inhibit the in vitro replication of 21 EV71 strains/isolates that are representative of the different genogroups A, B, and C[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 439085-51-5
-
Appearance Solid
-
Masse moléculaire 382.46
-
Formule C21H26N4O3
-
Color White to off-white
-
SMILES
CCOC1=NOC2=CC(OCCC3CCN(C4=CC=C(C)N=N4)CC3)=CC=C12
-
Synonyms
BTA798
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Eur J Med Chem
Design and synthesis of novel thioether analogs as promising antiviral agents: In vitro activity against enteroviruses of interest. [Abstract]2025 Apr 15:288:117395. PMID: 39986184 -
ACS Infect Dis
Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. [Abstract]2020 May 8;6(5):882-890. PMID: 32233455 -
-
Solvant et solubilité
DMSO : 5 mg/mL (13.07 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (269 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Tijsma A, et al. The capsid binder Vapendavir and the novel protease inhibitor SG85 inhibit enterovirus 71 replication. Antimicrob Agents Chemother. 2014 Nov;58(11):6990-2. [Content Brief]
[2]. Sun L, et al. Antiviral Activity of Broad-Spectrum and Enterovirus-Specific Inhibitors against Clinical Isolates of Enterovirus D68. Antimicrob Agents Chemother. 2015 Dec;59(12):7782-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6147 mL | 13.0733 mL | 26.1465 mL | 65.3663 mL |
| 5 mM | 0.5229 mL | 2.6147 mL | 5.2293 mL | 13.0733 mL | |
| 10 mM | 0.2615 mL | 1.3073 mL | 2.6147 mL | 6.5366 mL |